摘要
目的:探讨膦甲酸钠治疗慢性重型乙型肝炎的疗效。方法:128例重型乙型肝炎患者随机分为对照组63例,给予治疗常规治疗;治疗组65例,在常规治疗基础上加用膦甲酸钠治疗,膦甲酸钠注射液2.4g/250m l,2次/d,疗程28d。结果:肝功能复常率、HBVDNA的阴转率治疗组优于对照组(P<0.001)。治疗组肝性脑病、感染、肝肾综合征发生率分别为23.1%(15/65)、15.4%(10/65)、29.2%(19/65)明显低于对照组46.0%(29/63)、33.3%(21/63)、47.6%(30/63)差异有统计学意义(P<0.001)。病死率:治疗组29.2%(19/65),显著低于对照组52.3%(33/63)(P<0.01)。结论:在基础保肝支持治疗同时,及时应用膦甲酸钠能显著提高慢性乙型重型肝炎的抢救成功率。
Obiective： To investigate the effectiveness of foscarnet sodium in the treatment of patients with chronic severe hepatitis B. Methods： 128 patients were randomly put into a conventional supporting treatment control group and a foscarnet sodium treatment group . In the latter, 65 patients were given foscarnet sodium injection besides the support care which was also given to the control group. Results： The rate of death in the foscarnet sodium treatment group was significantly lower than control group（29.2% vs 52.3% , P〈0. 01）. There was significant difference between two group in the recovery of liver function and HBVDNA negative rate, In addition , the rate of hepatic coma（23. 1% vs 46. 0% P〈 0. 01） ,infection（15.4% vs33.3% P〈0. 0 5） , and hepatic kidney failure（29. 2% vs47.6% P〈0.05） in the foscarnet sodium treatment group were significant lower than control group. Conclusions： Our results suggest that foscarnet sodium administration with conventional supporting treatment has a good effect in patients with chronic severe hepatitis B.
出处
《陕西医学杂志》
CAS
北大核心
2007年第6期732-734,共3页
Shaanxi Medical Journal
